Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 9:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Efficacy Clear all
Completed Phase 2 Interventional

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease

NCT00185042
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Pactimibe, CS-505
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
46
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2007 · Synced Sep 18, 2026, 9:42 PM EDT
Terminated Phase 2 Interventional Results available

Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

NCT06784973
View directory record Official record
Conditions
RSV Infection
Interventions
Obeldesivir, Obeldesivir Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 5 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
41
States / cities
Birmingham, Alabama • Oneonta, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 18, 2026, 9:42 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

NCT03069469
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Tenosynovial Giant Cell Tumor, Diffuse
Interventions
Vimseltinib
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
9
States / cities
Palo Alto, California • Denver, Colorado • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 18, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

NCT01101841
View directory record Official record
Conditions
Hot Flashes
Interventions
Brisdelle (paroxetine mesylate), Placebo capsules
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
40 Years and older · Female only
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
32
States / cities
Montgomery, Alabama • Chandler, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 18, 2026, 9:42 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage

NCT00978822
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Hypertension
Interventions
Clevidipine butyrate injectable emulsion
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 18, 2026, 9:42 PM EDT
Active, not recruiting Phase 3 Interventional

NOVOCART®3D for Treatment of Articular Cartilage of the Knee

NCT01957722
View directory record Official record
Conditions
Articular Cartilage of the Femoral Condyle Between 2-6cm2
Interventions
Microfracture, NOVOCART 3D
Procedure · Biological
Lead sponsor
Aesculap Biologics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
30
States / cities
La Mesa, California • Los Angeles, California • Redwood City, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 18, 2026, 9:42 PM EDT
Completed Phase 2 Interventional

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia

NCT00378131
View directory record Official record
Conditions
Cancer Cachexia
Interventions
RC-1291, placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
17
States / cities
Glendale, Arizona • Encinitas, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2013 · Synced Sep 18, 2026, 9:42 PM EDT
Recruiting Phase 2 Interventional

High Dose Albumin in Refractory Ascites

NCT05867602
View directory record Official record
Conditions
Ascites
Interventions
Albumin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 18, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

NCT02615002
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Piromelatine, Placebo
Drug
Lead sponsor
Neurim Pharmaceuticals Ltd.
Industry
Eligibility
60 Years to 85 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
56
States / cities
Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 18, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

NCT04313153
View directory record Official record
Conditions
Anemia
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Chula Vista, California • Granada Hills, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 18, 2026, 9:42 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

NCT01669980
View directory record Official record
Conditions
Infections, Pneumonia
Interventions
Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange County, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2015 · Synced Sep 18, 2026, 9:42 PM EDT
Terminated Phase 3 Interventional

A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients

NCT00391196
View directory record Official record
Conditions
Obesity
Interventions
Placebo, CP-945,598, CP-945,598 Treatment B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 18, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301

NCT05286762
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Attention Deficit Hyper Activity
Interventions
CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
6 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 18, 2026, 9:42 PM EDT
Withdrawn Phase 2 Interventional

BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases

NCT04183062
View directory record Official record
Conditions
Osteosarcoma Metastatic, Ewing's Sarcoma Metastatic
Interventions
Chemotherapy (gemcitabine & docetaxel) plus BIO-11006
Drug
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
5 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Sep 18, 2026, 9:42 PM EDT
Not yet recruiting Phase 2 Interventional

A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

NCT07773727
View directory record Official record
Conditions
Immunoglobulin A Nephropathy (IgAN)
Interventions
ARGX-121, Placebo
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Miami, Florida • Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 18, 2026, 9:42 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Treatment Device

NCT03788486
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
2-3 Joule LED blue light device
Device
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Germantown, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 18, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis

NCT00267969
View directory record Official record
Conditions
Psoriasis
Interventions
ustekinumab, placebo
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • Redwood City, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2013 · Synced Sep 18, 2026, 9:42 PM EDT
Active, not recruiting Phase 2 Interventional

A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)

NCT07157254
View directory record Official record
Conditions
Angelman Syndrome
Interventions
No intervention, GTX-102
Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
1 Year to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 18, 2026, 9:42 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Healthy Mom Zone Gestational Weight Gain Management Intervention 2.0

NCT05807594
View directory record Official record
Conditions
Gestational Weight Gain, Overweight and Obesity, Pregnancy, Energy Balance
Interventions
HMZ 2.0 Intervention, Attention Control Intervention
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 18, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa

NCT01693029
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease (CKD)
Interventions
HX575 epoetin alfa, US-licensed epoetin alfa
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
52
States / cities
Tempe, Arizona • Azusa, California • Bakersfield, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 18, 2026, 9:42 PM EDT
Completed Not applicable Interventional

Home Testing of Day and Night Closed Loop With Pump Suspend Feature

NCT02523131
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases
Interventions
FlorenceM, Medtronic insulin pump 640G
Device
Lead sponsor
University of Cambridge
Other
Eligibility
6 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Aurora, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 18, 2026, 9:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish

NCT03110029
View directory record Official record
Conditions
Onychomycosis of Toenail
Interventions
Efinaconazole 10% Topical Application Solution [JUBLIA], Application of Nail Polish
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 70 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Sep 18, 2026, 9:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorolac Tromethamine Ophthalmic Solution) 0.45%, in Post-PRK Corneal Wound Healing

NCT01193231
View directory record Official record
Conditions
Must be PRK Candidate
Interventions
Not listed
Lead sponsor
Durrie Vision
Other
Eligibility
18 Years to 39 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Sep 18, 2026, 9:42 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Implementation Trial to Evaluate a Population Health Combination Intervention to Meet HIV Testing, Linkage, and Viral Suppression Goals in Alabama

NCT05384145
View directory record Official record
Conditions
HIV, HIV Linkage to Care, HIV Testing, HIV Treatment
Interventions
COAST-AL
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
13 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 18, 2026, 9:42 PM EDT